What's Happening?
Regeneron is actively recruiting an Executive Director, Global Lung Marketing, to lead and shape the commercialization and performance of its oncology solid tumor products, specifically within lung cancer indications, on a global scale. This role, based
in Sleepy Hollow, NY, requires the individual to be a member of the Oncology Business Unit and hold full accountability for the U.S. strategy and performance. The Executive Director will be responsible for setting the global tumor-level vision, leading both home-office and field marketing teams, and ensuring alignment with commercial imperatives. Key duties include driving cross-functional integration across U.S. and International Teams, critically assessing growth strategies in a competitive environment, and demonstrating strong competency in launching new products. The position emphasizes bringing Regeneron science to lung cancer patients and delivering consistent commercial impact. The role demands a minimum of 15 years of progressive experience in pharmaceutical marketing, brand strategy, and execution, with a preference for oncology and NSCLC experience.
Why It's Important?
This executive hire is crucial for Regeneron's strategic growth in the highly competitive oncology market, particularly within lung cancer. The individual will directly influence the commercial success of Regeneron's solid tumor products, impacting revenue streams and market share in the U.S. and globally. Their ability to drive growth in mature brands and successfully launch new ones will be vital for the company's financial performance and its standing against other pharmaceutical giants. The role's emphasis on integrating U.S. and International Teams highlights a unified global strategy, which is essential for maximizing market penetration and ensuring consistent messaging. Effective commercialization of these products can lead to improved patient access to innovative treatments, potentially enhancing public health outcomes for lung cancer patients. The successful candidate will also play a significant role in budget management and strategic planning, directly affecting resource allocation and long-term investment decisions within Regeneron's oncology portfolio.
What's Next?
The immediate next step for Regeneron is to successfully fill this Executive Director position. Once appointed, the new leader will be tasked with developing and implementing global tumor strategies, overseeing brand planning, and collaborating closely with clinical and medical affairs teams. They will need to conduct global market analyses, translate insights into strategic choices, and prioritize initiatives to drive differentiation and portfolio value. The Executive Director will also manage a team of direct reports, ensuring alignment with the global vision and providing direction for critical activities. Future actions will involve creating processes for commercial launch and marketing efforts, proactively addressing hurdles in oncology asset commercialization, and maintaining oversight of the global profit and loss for lung cancer products. The role will also involve engaging with global physician experts and attending key congresses to stay abreast of market developments and foster professional relationships.
Beyond the Headlines
Beyond the immediate commercial objectives, this role signifies Regeneron's commitment to advancing its oncology pipeline and addressing a critical public health challenge. The focus on lung cancer, a leading cause of cancer-related deaths, underscores the ethical imperative of bringing effective treatments to patients. The Executive Director's success will not only be measured in sales figures but also in the broader impact on patient lives and the medical community's ability to combat lung cancer. The position's global scope highlights the interconnectedness of healthcare markets and the need for a unified approach to drug development and commercialization. Furthermore, the emphasis on an inclusive culture and equal opportunity in the hiring process reflects broader societal expectations for corporate responsibility within the pharmaceutical industry. The role also touches upon the complex interplay between scientific innovation, regulatory environments, and market access, which are crucial for translating research into tangible patient benefits.
